Amphastar Pharmaceuticals (AMPH) Plunges 2.17% to 2022 Low

Amphastar Pharmaceuticals (AMPH) shares fell 2.17% today, marking the second consecutive day of decline, with a total drop of 5.86% over the past two days. The stock price hit its lowest level since January 2022, experiencing an intraday decline of 3.66%.

Recent performance concerns have weighed heavily on Amphastar Pharmaceuticals' stock. Over the past six months, the stock has plummeted by 50.3%, raising alarm among shareholders. Despite the company's strong fundamentals, the market's reaction indicates skepticism about its future prospects.

Analysts have offered mixed views on the company's outlook. Capital One Financial analyst Tim Chiang has maintained a buy rating for Amphastar Pharmaceuticals, setting a target price of $70. This suggests that some market analysts remain optimistic about the company's potential, despite the recent downturn in stock performance.